Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Lyumjev ® ▼ (insulin lispro)
Lyumjev® ▼ (insulin lispro): Transitioning From Prandial or Other Insulins
If converting from another mealtime insulin to Lyumjev, the change can be done on a unit-to-unit basis.
If transitioning from another mealtime insulin to Lyumjev, the change can be done on a unit-to-unit basis.1
Individualize and adjust the dosage of Lyumjev based on
the patient’s metabolic needs
BG monitoring results, and
glycemic control goal.1
To minimize the risk of hypoglycemia or hyperglycemia, Lyumjev dose adjustments may be needed
when transitioning from another insulin
when changes in physical activity
when changes in concomitant medications
when changes in meal patterns such as amount and type of food, timing of food intake
changes in renal or hepatic function, or
during acute illness.1
BG = blood glucose
URLi = ultra rapid lispro
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: January 16, 2020